•
Creampuff
Talks about Short Story, Short Fiction and Mystery
RH
Rob Hart
Director at Promptly Patient Experience Suite
Miami, Florida
Overview
Rob Hart is a Partner at Telegraph Hill Partners in Miami, Florida, specializing in venture capital, corporate development, and entrepreneurship. With a background in corporate law and a diverse portfolio of investments in healthcare information technology and biotech sectors, Rob has successfully invested in companies like Promptly and Nivagen Pharmaceuticals.
Rob's career highlights include serving as a Director for various companies such as Frontier Psychiatry and Nimble Therapeutics, and investing in successful ventures like Promptly and Aquaro Histology. His expertise in strategic planning and business strategy has contributed to his role as a Partner at Telegraph Hill Partners, where he continues to make impactful investments in innovative startups.
Work Experience
Partner
2007 - Current
Life science and health technology venture capital, growth equity and mission-driven company building
Telegraph Hill Partners is a venture capital firm investing in life sciences, medical device, and healthcare technology companies.
Director
2024
Web-based patient experience and automation suite for medical practices
Promptly is a web-based patient experience and automation suite designed for medical practices.
Founding Investor, Director
2024
Cells as reagents
Director
2023
Providing rural market access to exceptional mental healthcare
Director
2023
Home-based, community and remote health care for those in need
Director
2020
Specialty and generic pharmaceuticals, re-shoring
Nivagen Pharmaceuticals engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Raised $31,000,005.00 from Telegraph Hill Partners.
Director
2019
Peptide drug discovery
Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.
Raised $10,000,000.00 from Telegraph Hill Partners.
Director
2019
Safeguarding patients through monitoring compliance IT/hardware
Invisalert Solutions develops a patient-monitoring system that reduces risk, errors, and costs related to sentinel and non-sentinel events.
Raised $15,883,335.00 from Telegraph Hill Partners.
Director
2017 - 2023
Unlocking power of NGS for human identification. Acquired by Qiagen (NYSE:QGEN)
Secretary and Board Observer
2019 - 2022
Rapid antibiotic susceptibility testing. Acquired by bioMérieux S.A. (ENXTPA:BIM)